Head to Head Survey: JATT Acquisition (NYSE:JATT) versus Protalix BioTherapeutics (NYSE:PLX)

JATT Acquisition (NYSE:JATT) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Valuation & Earnings

This table compares JATT Acquisition and Protalix BioTherapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
JATT Acquisition	N/A	N/A	$6.85 million	N/A	N/A
Protalix BioTherapeutics	$61.84 million	3.36	$8.31 million	$0.07	36.93

Protalix BioTherapeutics has higher revenue and earnings than JATT Acquisition.

Analyst Ratings

This is a summary of current ratings and target prices for JATT Acquisition and Protalix BioTherapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
JATT Acquisition	0	0	0	0	0.00
Protalix BioTherapeutics	0	0	1	0	3.00

Protalix BioTherapeutics has a consensus price target of $12.00, indicating a potential upside of 364.22%. Given Protalix BioTherapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Protalix BioTherapeutics is more favorable than JATT Acquisition.

Insider & Institutional Ownership

48.0% of JATT Acquisition shares are held by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are held by institutional investors. 20.0% of JATT Acquisition shares are held by insiders. Comparatively, 6.5% of Protalix BioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares JATT Acquisition and Protalix BioTherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
JATT Acquisition	N/A	-49.58%	2.84%
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

Summary

Protalix BioTherapeutics beats JATT Acquisition on 6 of the 10 factors compared between the two stocks.

About JATT Acquisition

JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.